Celvivo key facts
as of Oct 2026- Developer of a 3D cell culture technology designed to grow cells so that they retain or recover their in vivo physiological attributes.
- Celvivo is valued at approximately $25.7M as of Oct 2026 (last reported valuation).
- It has raised $10.9M; the latest was Later Stage VC ($7.7M) in May 2025.
- Notable investors include Denmark's Export and Investment Fund, T&W Medical, EUREKA Network, Innovationsfonden.
- Status: Privately Held (backing).
Celvivo's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·Watch Celvivo: the Monday email on marks, rounds and moves
Celvivo funding rounds
No funding rounds for Celvivo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Celvivo valuation
Celvivo's last reported valuation was $25.7 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Celvivo investors
4 investors are on record for Celvivo, including Denmark's Export and Investment Fund, T&W Medical, EUREKA Network and Innovationsfonden.
About Celvivo
Developer of a 3D cell culture technology designed to grow cells so that they retain or recover their in vivo physiological attributes. The company's technology system creates an environment that promotes the growth and maintenance of large 3D tissue mimetic structures, whether they are spheroids, organoids, or other aggregates, enabling scientists from widely different areas to conduct research with cell cultures that mimic cells in the living organism.
- Sector
- Healthcare
- HQ
- Odense, Denmark
- Founded
- 2014
- Employees
- 30
- Website
- celvivo.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.